UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Volltextzugriff (PDF)

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Volltextzugriff (PDF)

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, obesity & metabolism, 2015-07, Vol.17 (7), p.630-638

2015

Volltextzugriff (PDF)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.883-892

2019

Volltextzugriff (PDF)

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Current opinion in urology, 2020-01, Vol.30 (1), p.98-105

2020

Volltextzugriff (PDF)

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Volltextzugriff (PDF)

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.523-532

2011

Volltextzugriff (PDF)

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1513-1520

2017

Volltextzugriff (PDF)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.567-576

2011

Volltextzugriff (PDF)

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.487-494

2015

Volltextzugriff (PDF)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Archives of Endocrinology and Metabolism, 2018-08, Vol.62 (4), p.424-430

2018

Volltextzugriff (PDF)

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1253-1262

2016

Volltextzugriff (PDF)

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Volltextzugriff (PDF)

Is 177 Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?

Hellenic journal of nuclear medicine, 2020-09, Vol.23 (3), p.312

2020

Volltextzugriff (PDF)

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Oncotarget, 2017-01, Vol.8 (2), p.3581-3590

2017

Volltextzugriff (PDF)

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.850-858

2011

Volltextzugriff (PDF)

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Volltextzugriff (PDF)

Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage

World journal of gastroenterology : WJG, 2008-01, Vol.14 (3), p.474-478

2008

Volltextzugriff (PDF)

Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial

Zhonghua gan zang bing za zhi, 2013-07, Vol.21 (7), p.528

2013

Volltextzugriff (PDF)

Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels

Zhonghua gan zang bing za zhi, 2013-05, Vol.21 (5), p.385

2013

Volltextzugriff (PDF)

Alanyl-glutamine dipeptide inhibits hepatic ischemia-reperfusion injury in rats

World journal of gastroenterology : WJG, 2006-03, Vol.12 (9), p.1373

2006

Volltextzugriff (PDF)

Management of Dry Eye Toxicity After Treatment With 177 Lu-PSMA-617 Radioligand Therapy

Practical radiation oncology, 2024-07, Vol.14 (4), p.301

2024

Volltextzugriff (PDF)

177 Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment

Current radiopharmaceuticals, 2024, Vol.17 (4), p.356

2024

Volltextzugriff (PDF)

Study on L-Ornithine-L-Aspartate in the treatment of acute-on-chronic liver failure

Zhonghua gan zang bing za zhi, 2011-01, Vol.19 (1), p.63

2011

Volltextzugriff (PDF)

Role of cathepsin B-mediated apoptosis in fulminant hepatic failure in mice

World journal of gastroenterology : WJG, 2009-03, Vol.15 (10), p.1231-1236

2009

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

KollektionMEDLINE

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(35)

Publikationsform

Artikel
(93)
Tagungsberichte
(1)

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Dipeptides - Therapeutic Use
(79)
Humans
(70)
Female
(54)
Middle Aged
(53)
Science & Technology
(44)
Life Sciences & Biomedicine
(43)
Adult
(40)
Aged
(36)
Animals
(27)
Treatment Outcome
(21)
Dipeptides - Administration & Dosage
(19)
Double-Blind Method
(17)
Adamantane - Analogs & Derivatives
(16)
Diabetes Mellitus, Type 2 - Drug Therapy
(16)
Endocrinology & Metabolism
(16)
Rats
(15)
Adamantane - Therapeutic Use
(14)
Dipeptides - Adverse Effects
(14)
Adolescent
(12)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Is 177 Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis?

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage

Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial

Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels

Alanyl-glutamine dipeptide inhibits hepatic ischemia-reperfusion injury in rats

Management of Dry Eye Toxicity After Treatment With 177 Lu-PSMA-617 Radioligand Therapy

177 Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment

Study on L-Ornithine-L-Aspartate in the treatment of acute-on-chronic liver failure

Role of cathepsin B-mediated apoptosis in fulminant hepatic failure in mice

Aktive Filter

Suchergebnisse filtern